Drugs / Bacteriophage
Bacteriophage
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07275905 | Aug 2026 → Jan 2028 expected | bacterial infectious disease, cystic fibrosis | Ghady Haidar | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05182749 | Feb 2023 → Dec 2024 overdue | shigellosis | Intralytix, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05010577 | Jun 2022 → Mar 2024 | Pseudomonas aeruginosa infectious disease, cystic fibrosis | BiomX, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05269134 | Mar 2023 → Jul 2025 | periprosthetic joint infection | Adaptive Phage Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06870409 | Feb 2025 → Feb 2028 expected | bacterial endocarditis | University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba) | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04325685 | Jan 2020 → Dec 2021 | acute respiratory distress syndrome, brain injury, encephalitis, epilepsy +3 | Northern State Medical University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07612605 Comparator | Jun 2026 → Dec 2028 expected | pneumonia | Chinese PLA General Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bacteriophage | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05269134 ↗ |
| Known as | AchromoPhage | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07275905 ↗ |
| Known as | BX004-A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05010577 ↗ |
| Known as | Sextaphag | “Bacteriophage (Sextaphag) group” NCT04325685 ↗ |
| Known as | ShigActive | “ShigActive is a collection of bacteriophages.” NCT05182749 ↗ |
| Action | Inhibit | “ShigActive is intended to significantly reduce or eliminate Shigella levels in the human gastrointestinal tract” NCT05182749 ↗ |
| Modality | Other / unclassified | “bacteriophage” NCT04325685 ↗ |
| Route | Other | “Oropharyngeal decontamination with bacteriophage” NCT04325685 ↗ |